Authors
K Subhalakshmi, Vishnu Priya Veeraraghavan, Ananthi Sivagnanam, Balasankar Thangasamy, Arul Prakash Francis
Published in
3 Biotech. Volume 16. Issue 8. Pages 299. Epub Jul 04, 2026.
Abstract
Breast cancer remains the most common cancer among women and a major cause of mortality. Fisetin, a natural compound, has demonstrated anti-cancer activity, but its limited bioavailability reduces its therapeutic effect. To overcome this, glucose-capped fisetin silver nanoparticles (GF-Ag NPs) were synthesised, and their significant impact on the MDA-MB-231 breast cancer cell line is reported. This study focused on the proteomic profiling of GF-Ag NP-treated MDA-MB-231 cells using two-dimensional gel electrophoresis and mass spectrometry, which identified 25 proteins with altered expression. Gene ontology and protein-protein interaction analyses indicated these proteins are involved in critical biological and molecular processes. Four key proteins-Nucleolin (NCL), Tropomyosin alpha-4 chain (TPM4), L-lactate dehydrogenase A (LDHA), and Peroxiredoxin-1 (PRDX1)-were chosen for further validation through qRT-PCR based on their relevance to cancer progression. Additionally, bioinformatic prediction tools identified several miRNAs (such as miR-577, miR-205-5p, miR-613, miR-206, and miR-374b-5p) and associated lncRNAs as regulators of these proteins. These results suggest that GF-Ag NPs can modulate the expression of key genes and signalling pathways involved in breast cancer progression and apoptosis.
The online version contains supplementary material available at 10.1007/s13205-026-04930-9.
PMID:
42404972
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0